Assess the relationship between metformin use and prostate cancer risk in obese non-diabetic men.
Observational study design
Focus on obese men
Investigated metformin prescription rates
Analyzed prostate cancer incidence
Metformin use is linked to a lower risk of advanced prostate cancer.
Risk reduction is significant in early detection cases.
Findings support the potential repurposing of metformin for prostate cancer management.
Abstract
Metformin-use in obese men is associated with reduced PC risk, if detected early. Further research could inform the repurposing of metformin for PC control.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Cite This Study
Nair-Shalliker et al. (Tue,) studied this question.